Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

Abstract

The human epidermal growth factor receptor (HER1/EGFR) is dysregulated in many solid tumors, making it an attractive target for anticancer therapy. A number of agents that target this receptor are in use or in development. A specific adverse effect common to this class of agent is a papulopustular rash, usually on the face and upper torso, which generally… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.